Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brain connectivity and patient reported outcomes in people with HIV with insomnia switching integrase inhibitor-based ART
2019-004007-12Phase 4Unknown
- Sponsor
- University of Sussex
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bictegravir + emtricitabine + tenofovir alafenamide, abacavir, bictegravir, dolutegravir, emtricitabine and 2 more in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Sussex. Primary endpoint: Change in MRI cerebral function parameters and patient reported outcomes. Status: unknown.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamideabacavirbictegravirdolutegraviremtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2019-004007-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004007-12.